These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 19329941)

  • 1. Glypican-3 expression in clear cell adenocarcinoma of the ovary.
    Maeda D; Ota S; Takazawa Y; Aburatani H; Nakagawa S; Yano T; Taketani Y; Kodama T; Fukayama M
    Mod Pathol; 2009 Jun; 22(6):824-32. PubMed ID: 19329941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glypican-3 expression predicts poor clinical outcome of patients with early-stage clear cell carcinoma of the ovary.
    Umezu T; Shibata K; Kajiyama H; Yamamoto E; Nawa A; Kikkawa F
    J Clin Pathol; 2010 Nov; 63(11):962-6. PubMed ID: 20972242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "Piling up" clear cells in müllerian-type mucinous and mixed cell-type borderline tumor do not represent concomitant clear cell neoplasms.
    Ohishi Y; Kurihara S; Aman M; Takeuchi T; Imamura H; Kaku T; Kobayashi H; Wake N; Oda Y
    Hum Pathol; 2012 Oct; 43(10):1618-26. PubMed ID: 22436624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of podoplanin in epithelial ovarian carcinomas and its potential as a marker for clear cell adenocarcinoma.
    Oe S; Hasegawa K; Nagase S; Kato R; Torii Y; Udagawa Y
    Int J Gynecol Pathol; 2010 Sep; 29(5):405-10. PubMed ID: 20736762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient.
    Yamamoto S; Tsuda H; Miyai K; Takano M; Tamai S; Matsubara O
    Mod Pathol; 2011 Aug; 24(8):1146-55. PubMed ID: 21478826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype.
    Köbel M; Xu H; Bourne PA; Spaulding BO; Shih IeM; Mao TL; Soslow RA; Ewanowich CA; Kalloger SE; Mehl E; Lee CH; Huntsman D; Gilks CB
    Mod Pathol; 2009 Mar; 22(3):469-75. PubMed ID: 19136932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth-suppressing function of glypican-3 (GPC3) via insulin like growth factor II (IGF-II) signaling pathway in ovarian clear cell carcinoma cells.
    Sakurai M; Shibata K; Umezu T; Kajiyama H; Yamamoto E; Ino K; Nawa A; Kikkawa F
    Gynecol Oncol; 2010 Nov; 119(2):332-6. PubMed ID: 20701957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Use of Napsin A and Glypican 3 to Distinguish Endometrial Clear Cell from Serous and Endometrioid Carcinomas.
    Miller EM; Tymon-Rosario J; Sunkara J; Harmon BE; Karabakhtsian RG; Novetsky AP
    Int J Gynecol Cancer; 2018 Sep; 28(7):1318-1324. PubMed ID: 30036224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of HER-2/neu is not a risk factor in ovarian clear cell adenocarcinoma.
    Tanabe H; Nishii H; Sakata A; Suzuki K; Mori Y; Shinozaki H; Watanabe A; Ochiai K; Yasuda M; Tanaka T
    Gynecol Oncol; 2004 Sep; 94(3):735-9. PubMed ID: 15350366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types.
    Wang H; Rosen DG; Wang H; Fuller GN; Zhang W; Liu J
    Mod Pathol; 2006 Sep; 19(9):1149-56. PubMed ID: 16729015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemistry expression of targeted therapies biomarkers in ovarian clear cell and endometrioid carcinomas (type I) and endometriosis.
    Barreta A; Sarian LO; Ferracini AC; Costa LBE; Mazzola PG; de Angelo Andrade L; Derchain S
    Hum Pathol; 2019 Mar; 85():72-81. PubMed ID: 30447298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sox10 expression in ovarian epithelial tumors is associated with poor overall survival.
    Kwon AY; Heo I; Lee HJ; Kim G; Kang H; Heo JH; Kim TH; An HJ
    Virchows Arch; 2016 May; 468(5):597-605. PubMed ID: 26951260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of NEU3 (plasma membrane-associated sialidase) in clear cell adenocarcinoma of the ovary: its relationship with T factor of pTNM classification.
    Nomura H; Tamada Y; Miyagi T; Suzuki A; Taira M; Suzuki N; Susumu N; Irimura T; Aoki D
    Oncol Res; 2006; 16(6):289-97. PubMed ID: 17476974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rsf-1 (HBXAP) expression is associated with advanced stage and lymph node metastasis in ovarian clear cell carcinoma.
    Maeda D; Chen X; Guan B; Nakagawa S; Yano T; Taketani Y; Fukayama M; Wang TL; Shih IeM
    Int J Gynecol Pathol; 2011 Jan; 30(1):30-5. PubMed ID: 21131837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glypican-3 expression in primary and recurrent ovarian carcinomas.
    Stadlmann S; Gueth U; Baumhoer D; Moch H; Terracciano L; Singer G
    Int J Gynecol Pathol; 2007 Jul; 26(3):341-4. PubMed ID: 17581422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of CXCR4 indicates poor prognosis in patients with clear cell carcinoma of the ovary.
    Sekiya R; Kajiyama H; Sakai K; Umezu T; Mizuno M; Shibata K; Yamamoto E; Fujiwara S; Nagasaka T; Kikkawa F
    Hum Pathol; 2012 Jun; 43(6):904-10. PubMed ID: 22169254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Napsin A is a specific marker for ovarian clear cell adenocarcinoma.
    Yamashita Y; Nagasaka T; Naiki-Ito A; Sato S; Suzuki S; Toyokuni S; Ito M; Takahashi S
    Mod Pathol; 2015 Jan; 28(1):111-7. PubMed ID: 24721826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.
    Zheng W; Yi X; Fadare O; Liang SX; Martel M; Schwartz PE; Jiang Z
    Am J Surg Pathol; 2008 Feb; 32(2):304-15. PubMed ID: 18223334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of INPP4B protein immunohistochemistry in ovarian cancer.
    Salmena L; Shaw P; Fans I; McLaughlin ; Rosen B; Risch H; Mitchell C; Sun P; Narod SA; Kotsopoulos J
    Eur J Gynaecol Oncol; 2015; 36(3):260-7. PubMed ID: 26189250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome.
    Byrne JA; Maleki S; Hardy JR; Gloss BS; Murali R; Scurry JP; Fanayan S; Emmanuel C; Hacker NF; Sutherland RL; Defazio A; O'Brien PM
    BMC Cancer; 2010 Sep; 10():497. PubMed ID: 20846453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.